Compare stocks

Pfizer Inc. (PFE) vs Merck & Co., Inc. (MRK)

Pfizer is cheaper with a larger dividend; Merck has stronger momentum and estimated earnings recovery

Pfizer and Merck are similar drug manufacturers, but the market prices them differently. Pfizer leads Qanvo's valuation category (forward P/E 9.61× vs 17.53×) and financial resilience (60 vs 40). Merck leads earnings momentum (67 vs 33), technical momentum (80 vs 20) and the lower-risk profile (75 vs 25). Growth and profitability & quality are mixed, with each at 50, so there is no clear leader. Merck's 1-year price return is 54.4% against 13.5% for Pfizer, while Pfizer's dividend yield is 6.04% against 2.37%. Both pay dividends above trailing earnings, and each forward view rests on analyst estimates.

Business overview

Both companies sit in Healthcare, in the Drug Manufacturers - General industry, and both trade on the NYSE. Merck is the larger at a market cap of $354.27B (mega tier) versus $162.28B for Pfizer (large tier), roughly double. Employee counts are close at 74,000 for Merck and 75,000 for Pfizer. Per its profile, Pfizer is a biopharmaceutical company covering discovery, development, manufacturing and marketing, with areas such as cardiovascular metabolic disorders, migraines, women's health and infectious diseases. Merck describes two divisions: Pharmaceuticals (oncology, immunology, neuroscience, virology, vaccines and others) and Animal Health (veterinary medicines and vaccines). The fiscal 2025 segment data shows the difference. Pfizer reports 97.79% of revenue from its Biopharma segment, while Merck's Pharmaceutical segment is 89.43% and Animal Health 9.77%. The United States is a similar share for both: 59.25% for Pfizer and 56.16% for Merck. The business models are broadly alike, so most ratios compare directly, with Merck's animal health unit the main structural difference.

  • Merck's market cap of $354.27B is roughly double Pfizer's $162.28B.
  • Pfizer draws 97.79% of fiscal 2025 revenue from one Biopharma segment, versus 89.43% for Merck's Pharmaceutical segment.
  • Merck's Animal Health segment adds 9.77% of revenue, with no equivalent disclosed for Pfizer.
  • US revenue share is 59.25% for Pfizer and 56.16% for Merck.

Valuation

Qanvo's scorecard names Pfizer the valuation leader (score 100 versus 0 for Merck, relative ranks within this pair). Pfizer's trailing P/E is 40.24× against 144.42× for Merck, and its forward P/E, an analyst-estimate-based multiple, is 9.61× versus 17.53×. Price/sales is 2.55× versus 5.26×, EV/EBITDA 15.64× versus 33.75×, and free-cash-flow yield 7.26% versus 4.16%. Merck's PEG is 0.08×; no PEG is given for Pfizer. Against its own 5-year range, Pfizer's trailing P/E of 40.24× sits above its median of 15.04× but well below the 78.21× peak. Merck's 144.42× is far above its median of 20.47× and below a maximum of 942.5×. Against sector peers, Pfizer's forward P/E is at the 7th percentile (sector median 18.34×); Merck's is at the 45th. Merck's trailing P/E is at the 97th percentile versus the 30.02× sector median. The cheaper multiple does not look purely like a discount. Pfizer's consensus next-year EPS growth is -3.08%, and its growth score is lowest-tier, while Merck's trailing multiple is inflated by depressed recent earnings. Merck's higher multiples partly reflect expected earnings recovery, which is an analyst estimate.

  • Pfizer's forward P/E of 9.61× compares with 17.53× for Merck.
  • Pfizer's free-cash-flow yield of 7.26% is above Merck's 4.16%.
  • Merck's trailing P/E of 144.42× is far above its 5-year median of 20.47×, while Pfizer's 40.24× is above its median of 15.04×.
  • Pfizer's forward P/E sits at the 7th sector percentile versus the 45th for Merck.

Growth

The scorecard calls growth mixed, with both companies at 50, so there is no clear leader. Reported revenue growth over the last year is 8.32% for Pfizer and 4.79% for Merck, but in the last quarter Merck grew 5.25% while Pfizer slipped -0.43%. Over three years Pfizer's revenue compound rate is -14.56% against 3.08% for Merck, reflecting Pfizer's fall from $100.33B in fiscal 2022 to $62.58B in fiscal 2025. Merck's revenue rose steadily from $59.28B to $64.93B over the same years. EPS tells a similar story of volatility. Trailing EPS growth is -67.88% for Pfizer and -87.19% for Merck, with 3-year EPS compounds of -37.12% and 8.43%. Merck posted quarterly net losses in Q1 and Q2 of fiscal 2026 before a profit in Q3 (EPS 2.04); Pfizer had one loss quarter (Q2). Analyst estimates diverge sharply: consensus next-fiscal-year EPS growth is -3.08% for Pfizer versus 221.14% for Merck, which is a rebound from a low base and an opinion, not a result. Merck's revenue has also been accelerating for 2 quarters, while Pfizer shows 0.

  • Last-year revenue growth is 8.32% for Pfizer versus 4.79% for Merck, but last-quarter growth is -0.43% versus 5.25%.
  • Three-year revenue compound is -14.56% for Pfizer and 3.08% for Merck.
  • Estimated next-year EPS growth is -3.08% for Pfizer against 221.14% for Merck.
  • Merck's revenue has accelerated for 2 quarters versus 0 for Pfizer.

Profitability, cash flow & financial health

Qanvo's profitability and quality scorecard shows no clear leader (50 for each), and the detail explains why. MRK has the higher gross margin (74.67% vs 73.37%) and FCF margin (21.91% vs 18.53%). PFE has the higher operating margin (23.83% vs 13.64%), net margin (6.34% vs 3.64%) and ROIC (8.72% vs 8.15%). ROE is slightly higher at MRK (5.07% vs 4.44%), and both are low. On cash flow, MRK produced trailing free cash flow of $14.75B against $11.79B for PFE, though PFE's free cash flow grew 85.83% year over year against 13.00% for MRK. Over the last year, operating margin fell 25.10% at MRK and 7.40% at PFE, so neither shows improving economics yet. Both companies' quarterly results have been uneven, with MRK posting losses in Q1 and Q2 FY2026 before a profit of $5.07B in Q3. On the balance sheet, PFE leads Qanvo's resilience score (60 vs 40). Its debt/equity is 0.70× against 1.20× at MRK. Net debt/EBITDA is similar (3.59× vs 3.74×). MRK has the higher interest coverage (6.19× vs 5.60×) and Altman Z-score (3.95 vs 2.27), while PFE has the higher current ratio (1.42× vs 1.35×).

  • MRK has the higher FCF margin (21.91% vs 18.53%), while PFE has the higher operating margin (23.83% vs 13.64%).
  • PFE's debt/equity is 0.70× against 1.20× at MRK, and net debt/EBITDA is close at 3.59× vs 3.74×.
  • Operating margin declined over the past year at both: 7.40% at PFE and 25.10% at MRK.
  • MRK's interest coverage is 6.19× against 5.60× for PFE.

Shareholder returns & capital allocation

The dividend is the biggest gap. PFE yields 6.04% on $1.72 per share over the trailing twelve months, against 2.37% and $3.40 for MRK. The payout ratio is above 100% at both, 246.84% for PFE and 350.52% for MRK, because trailing earnings are depressed. Reported earnings did not cover either payout, though the free cash flow figures above are larger than annual dividends at PFE ($9.77B paid in FY2025) and at MRK ($8.18B). Dividend growth favors MRK: 5.42% over three years against 2.44% for PFE, and both list 15 years of dividend growth. PFE's quarterly payment has been $0.43 throughout the period shown, while MRK's rose from $0.81 to $0.85. On share count, MRK is shrinking it (-0.60% over a year) and repurchased $5.08B of stock in FY2025. PFE's share count rose 0.65% and its annual data shows no repurchases in FY2023 to FY2025. PFE's capital goes mostly to the dividend, while MRK splits it between dividends and buybacks.

  • PFE's dividend yield is 6.04% against 2.37% for MRK.
  • Payout ratios are 246.84% for PFE and 350.52% for MRK, both above 100% of trailing earnings.
  • MRK's three-year dividend growth is 5.42% against 2.44% for PFE.
  • MRK's share count changed -0.60% over a year, while PFE's changed 0.65%.

Earnings intelligence

Both companies have beaten EPS consensus in each of the last four reported quarters, but MRK's reactions were larger. PFE's EPS surprises were 16.40% (Feb 3, 2026), 3.88% (May 5), 12.90% (Aug 4) and 18.37% (Nov 3), with revenue surprises of 4.20%, 4.41%, 4.41% and 4.61%. The stock moved 0.45%, 0.87%, 3.12% and 0.39% on those days. MRK's surprises were 1.49%, 12.93%, 51.94% and 19.14%, with revenue surprises of 1.24%, 2.77%, 1.45% and 4.35%; price moves were 4.38%, 1.09%, 0.44% and 6.10%. MRK's quarterly EPS actuals were negative in two of those quarters (-1.28 and -0.13), so those beats were against negative consensus figures. On estimate revisions, MRK's 30-day EPS revision is 4.70% versus 2.90% for PFE, and Qanvo's earnings momentum category favors MRK (67 vs 33). PFE has the longer beat streak, 25 quarters against 7. Both next report on Feb 2, 2027, and neither date is confirmed. The latest report strengthened MRK's relative case slightly more, given the larger surprise-driven reaction; PFE's 0.39% move suggests the beat was largely expected. Guidance is not given in the facts.

  • PFE's last EPS surprise was 18.37% versus 19.14% for MRK, nearly equal.
  • MRK's stock moved 6.10% on its latest report versus 0.39% for PFE.
  • PFE's EPS beat streak is 25 quarters versus 7 for MRK.
  • The 30-day EPS revision is 4.70% for MRK versus 2.90% for PFE (analyst estimates).

Technicals, relative performance & risk

MRK has led on price return over most periods. By price return, MRK is ahead over 1 month (-0.2% vs -3.3%), 6 months (27.4% vs 12.4%), 1 year (54.4% vs 13.5%), 3 years (39.6% vs -5.0%) and 5 years (73.6% vs -44.0%). PFE leads only over 3 months (6.0% vs 5.4%). With dividends reinvested, 5-year total return is 102.2% for MRK versus -27.7% for PFE, and PFE's dividend narrows its 1-year gap to 19.4% versus 58.9%. Both trade below their 20-day averages (PFE -4.08%, MRK -1.98%) and 50-day averages (PFE -1.23%, MRK -1.74%), and above the 200-day (PFE 5.42%, MRK 11.17%). RSI is 40.95 for PFE and 44.96 for MRK. PFE sits 9.45% below its 52-week high of 31.44 and MRK 8.63% below 156.92. The relative strength rating is 90 for MRK and 81 for PFE. On risk, MRK has the lower beta (0.24 vs 0.26 for PFE) and smaller 1-year drawdown (-11.90% vs -17.09%), though its 30-day historical volatility is higher (31.29% vs 23.92%). Strong technicals for MRK sit alongside its much higher valuation, where PFE leads, so the signals conflict.

  • MRK's 1-year price return is 54.4% versus 13.5% for PFE.
  • MRK's price is 11.17% above its 200-day average versus 5.42% for PFE.
  • MRK's 1-year drawdown is -11.90% versus -17.09% for PFE.
  • PFE's 30-day volatility is 23.92% versus 31.29% for MRK, so the lower-risk label for MRK rests on drawdown, beta and short interest.

Analyst & ownership sentiment

Analysts' opinions lean more favorably toward Merck. Its consensus label is Buy with a rating score of 2 from 14 analysts, and the detailed tally shows 26 Buy, 11 Hold and 1 Sell. Pfizer's label is Buy on a rating score of 2.5 from 13 analysts, while the detailed tally of 16 Buy, 23 Hold and 1 Sell is labelled Hold. These are opinions, not predictions. Mean price targets imply similar upside: $162.83 for Merck (13.57% above the price) and $32.33 for Pfizer (13.56%). Merck's target rests on 23 targets over three months versus 6 for Pfizer. Neither had upgrades or downgrades in the last 30 days. Estimate revisions over 30 days were 4.70% for Merck and 2.90% for Pfizer. Institutions hold 82.27% of Merck versus 67.94% of Pfizer, with three-month changes of 4.13% and 1.75%. These filings lag by weeks. Insiders differ: Pfizer's recent disclosed insider trades include purchases by its Chairman & CEO and two directors in August, while Merck shows one insider sale in the last 90 days, worth $8.6M net. Short interest is 2.36% of Pfizer's float versus 1.07% for Merck.

  • Merck's consensus tally has 26 Buy ratings versus 16 for Pfizer, which is labelled Hold on the detailed tally.
  • Mean targets imply 13.57% upside for Merck and 13.56% for Pfizer, essentially the same.
  • Institutional ownership is 82.27% for Merck versus 67.94% for Pfizer.
  • Short interest is 2.36% of float for Pfizer, over twice Merck's 1.07%.

Risks & catalysts

Valuation and estimate dependence differ in kind. Merck's trailing P/E is 144.42×, so its forward P/E of 17.53× depends on analysts' expected EPS growth of 221.14% next fiscal year, an estimate. Pfizer's forward P/E is 9.61×, but analysts expect EPS to fall 3.08% next fiscal year, and its payout ratio is 246.84%, against Merck's 350.52%, so both dividends exceed trailing earnings. Leverage is similar: net debt to EBITDA is 3.59× for Pfizer and 3.74× for Merck, though Merck's debt to equity is 1.20× versus 0.70×. Merck's operating margin fell 25.10% over a year, versus 7.40% for Pfizer. Volatility is higher for Merck: 30-day historical volatility is 31.29% versus 23.92%, with an expected 30-day move of 9.08% versus 7.53%. Merck also reported news on stopping blood cancer drug trials on Nov 17, 2026. The facts give no more detail on that. Catalysts: both report next on Feb 2, 2027, 77 days away, though neither date is confirmed. Merck's average earnings move over eight quarters is 3.84% versus 1.69% for Pfizer. Pfizer's last ex-dividend date was Nov 6, 2026, and Merck's was Sep 15, 2026.

  • Merck's forward P/E of 17.53× rests on an estimated 221.14% EPS rebound; Pfizer's 9.61× comes with estimated EPS down 3.08%.
  • Net debt to EBITDA is 3.74× for Merck versus 3.59× for Pfizer, near parity.
  • Merck's 30-day historical volatility is 31.29% versus 23.92% for Pfizer.
  • Both report Feb 2, 2027 (unconfirmed); Merck's average earnings move is 3.84% versus 1.69%.

Analysis written November 18, 2026. AI-generated, for information only; not investment advice.